Janney Montgomery Scott LLC acquired a new stake in Crispr Therapeutics AG (NASDAQ:CRSP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,990 shares of the company’s stock, valued at approximately $205,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CRSP. BSW Wealth Partners purchased a new stake in Crispr Therapeutics in the 2nd quarter valued at $39,000. Balyasny Asset Management LLC purchased a new stake in shares of Crispr Therapeutics in the second quarter valued at about $5,165,000. BNP Paribas Arbitrage SA acquired a new stake in shares of Crispr Therapeutics during the second quarter worth about $41,000. Bank of New York Mellon Corp boosted its stake in shares of Crispr Therapeutics by 116.5% during the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after buying an additional 17,810 shares during the period. Finally, ARK Investment Management LLC boosted its stake in shares of Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares during the period. Institutional investors own 49.82% of the company’s stock.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 in the last three months. Corporate insiders own 21.40% of the company’s stock.
Several equities analysts recently issued reports on the company. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Oppenheimer upped their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, November 25th. Finally, BidaskClub raised Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $69.54.
CRSP stock traded down $1.98 on Wednesday, reaching $65.65. 1,040,910 shares of the company’s stock were exchanged, compared to its average volume of 710,379. The firm has a market cap of $4.00 billion, a PE ratio of -19.08 and a beta of 3.30. Crispr Therapeutics AG has a twelve month low of $22.22 and a twelve month high of $74.00. The stock has a fifty day moving average of $57.87 and a 200-day moving average of $48.15. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. On average, equities research analysts predict that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: How can investors benefit from after-hours trading?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.